Suppr超能文献

肝细胞癌中p53基因突变谱

p53 gene mutation spectrum in hepatocellular carcinoma.

作者信息

Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S

机构信息

Pathology Division, National Cancer Center Research Institute, Tokyo, Japan.

出版信息

Cancer Res. 1992 Nov 15;52(22):6358-64.

PMID:1330291
Abstract

In order to clarify the significance of mutation of the p53 tumor suppressor gene in the genesis and development of human hepatocellular carcinoma (HCC) in an aflatoxin B1 low-exposure area, the spectrum, i.e., incidence, type, and site, of p53 gene mutations was examined in 169 tissue samples resected mainly from Japanese patients using single-strand conformation polymorphism analysis and direct sequencing. Forty-nine tumors (29%) showed a p53 mutation (39 point mutations and 10 frameshifts). The point mutations comprised 18 transitions, only 4 of which occurred at CpG sites, and 21 transversions. Two evolutionarily conserved domains, IV and V, contained 65% of all mutations and codon 249 was the most frequent mutation site (7/49). The spectrum of p53 mutation did not differ among HCCs in relation to the type of hepatitis virus infection, sex, age, and background liver disease of patients, tumor size, or presence of metastasis, but incidence and site were significantly associated with the degree of differentiation of cancer cells. In poorly differentiated HCC, p53 mutation was frequent (54%) and clustered on domains IV and V, whereas in well or moderately differentiated HCC, the mutation was less frequent (21%) and equally distributed on domains II to V. Restriction fragment length polymorphism analysis revealed loss of heterozygosity on chromosome 17p in 55 (69%) of 80 informative cases and in 34 (95%) of 36 cases with p53 mutation. Therefore, p53 gene mutation is suggested to occur independently of the type of viral infection or status of preexisting liver disease and to occur preferentially in moderately and poorly differentiated HCCs in association with or after loss of another p53 allele as a late event of HCC progression.

摘要

为了阐明在黄曲霉毒素B1低暴露地区人肝细胞癌(HCC)发生发展过程中p53肿瘤抑制基因突变的意义,我们采用单链构象多态性分析和直接测序法,检测了主要来自日本患者的169份切除组织样本中p53基因突变的谱,即发生率、类型和位点。49个肿瘤(29%)显示p53突变(39个点突变和10个移码突变)。点突变包括18个转换,其中仅4个发生在CpG位点,以及21个颠换。两个进化保守结构域IV和V包含所有突变的65%,密码子249是最常见的突变位点(7/49)。p53突变谱在不同的HCC中,与患者的肝炎病毒感染类型、性别、年龄、背景肝病、肿瘤大小或转移情况无关,但发生率和位点与癌细胞分化程度显著相关。在低分化HCC中,p53突变常见(54%)且集中在结构域IV和V,而在高分化或中分化HCC中,突变较少见(21%)且均匀分布在结构域II至V。限制性片段长度多态性分析显示,80例信息可分析病例中有55例(69%)以及36例p53突变病例中有34例(95%)在17号染色体短臂上发生杂合性缺失。因此,提示p53基因突变独立于病毒感染类型或原有肝病状态而发生,并且作为HCC进展的晚期事件,在另一个p53等位基因缺失时或之后,优先发生在中分化和低分化HCC中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验